Triple-negative breast cancer (TNBC) has become a serious threat to women's health.
Research on epigenetic drugs is gradually deepening and is expected to provide new …

Unlike other breast cancer subtypes, triple-negative breast cancer (TNBC) has no specific
targets and is characterized as one of the most aggressive subtypes of breast cancer that …

Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–
20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype …

Triple negative breast cancer (TNBC) is a type of breast cancer with poor prognosis, and has
no ideal therapeutic target and ideal medicine. Downregulation of JWA is closely related to …

The high mortality rate of breast cancer is mainly caused by the metastatic ability of cancer
cells, resistance to chemotherapy and radiotherapy, and tumor regression capacity. In recent …

Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …

Aim Polo‐like kinase‐1 (PLK1) plays a crucial role in cell cycle progression, and it is
considered a potential therapeutic target in many cancers. Although the role of PLK1 is well …

The family with sequence similarity 20, member C (Fam20C), a Golgi casein kinase, has
been recently regarded as a potential therapeutic target for the treatment of triple negative …

Controlled delivery of multiple chemotherapeutics can improve the effectiveness of
treatments and reduce side effects and relapses. Here in, we used albumin-stabilized gold …

Treatment of triple-negative breast cancer (TNBC) faces great challenges due to high
invasiveness and poor prognosis. Therefore, effective treatment methods are urgently …